Our current approach for determining adjuvant systemic therapy is to assess the primary tumor using traditional clinical and pathological features (e.g., young patient age, high tumor grade, large tumor size, lymph nodal involvement, lack of hormone receptor (HR) expression, and overexpression of HER2) or more recent molecular profiling tools (e.g., 21-gene OncotypeDx and 70-gene Mammaprint). Here, NR4A1 is linked to neoplasm.